Improved affordability and local production initiatives accelerate GLP-1 drugs adoption in the region
Persistent or severe digestive symptoms, dysphagia, or signs of pancreatitis require prompt medical assessment and should not be dismissed as routine side effects
In future, it is likely that the clinical indications for GLP- 1RAs will expand, with pharmaceutical companies running various drug trials to substantiate a wider array of use cases, such as the reduction of cardiovascular risk and the treatment of chronic kidney disease
This eliminates the medical oversight that makes combination therapy even remotely reasonable
The TriNetX platform has been used in retrospective cohort studies [25,26,27,28,29,30,31,32,33,34,35,36,37,38] including evaluating risk and health outcomes of patients with substance use disorders including CUD [25, 32, 35] and the associations of GLP-1RAs with cancer [37] and semaglutide with suicidal ideations [38]
This helps ensure maximum absorption and effectiveness